Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Therapy With or Without Nephrectomy in Metastatic Renal Cell Carcinoma
2015-002240-14Phase 3Completed
- Sponsor
- Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of sunitinib and pazopanib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Fondazione IRCCS - Istituto Nazionale dei Tumori di Milano. Primary endpoint: Overall Survival. Started Nov 2020; status: completed.
02
Drugs
sunitinibpazopanib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on 2015-002240-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-002240-14.